Physician profile
Ashlee Sloan
NPI 1568079036
$2,370.64
in general payments reported to CMS, 2019-2025
26 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $392 · 2023: $619 · 2024: $624 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $495.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $368.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $293.98 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $202.35 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $126.63 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.57 | 2022 | |
| Exact Sciences Corporation | $87.58 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $82.99 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $65.26 | 2021 | |
| Lilly USA, LLC | $65.00 | 2022-2024 | Mounjaro |
| Corcept Therapeutics | $57.75 | 2024 | Korlym |
| Amgen INC. | $57.27 | 2022-2023 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $45.99 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $45.25 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.20 | 2023-2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.82 | 2025 | Voquezna |
| Astellas Pharma US INC | $37.28 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.07 | 2021-2022 | |
| Dexcom, INC. | $22.64 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.51 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.36 | 2022 | |
| Axsome Therapeutics, INC. | $16.63 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $14.48 | 2023 | Krystexxa |
| Amarin Pharma, INC. | $14.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.13 | 2023 | Xarelto |
| Currax Pharmaceuticals LLC | $13.88 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Sloan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.